Cerbios-Pharma Expands Lugano Site for HPAPI and ADC Manufacturing

• Cerbios-Pharma has inaugurated an expanded manufacturing area at its Lugano site for HPAPIs, including cytotoxic linker payloads for ADCs.

• The new facility is equipped with isolator containment technology and advanced purification capabilities to meet growing market demand.

Cerbios-Pharma has announced the opening of a new manufacturing expansion at its Lugano site, enhancing its capabilities for clinical and commercial production of Highly Potent Active Pharmaceutical Ingredients (HPAPIs). The facility will also support cytotoxic linker payloads for antibody-drug conjugates (ADCs). The inauguration was attended by CEO Christian Suà and members of the Cerbios team.

The new unit features isolator containment technology designed for highly potent molecules with an occupational exposure limit (OEL) of less than 10 ng/m3. This ensures a high level of flexibility, allowing the production of a broad range of complex molecules while maintaining stringent safety and quality standards.

With this investment, Cerbios-Pharma expands its capacity for advanced purification technologies, including high- and low-pressure chromatography, nanofiltration, and freeze-drying. The new facility is located within a recently constructed building that was approved by Swissmedic in 2023, providing immediate additional capacity to meet increasing market demand.